Category : Search result: VinFast quarterly loss


Ozempic Penis: The Truth Behind Viral Claim

Discover the truth about 'Ozempic penis' - the viral claim about GLP-1 medications. Urologists explain why it's an optical illusion and reveal real sexual side effects.

Senators Settle for Point in 3-2 OT Loss to Stars

The Ottawa Senators earned a single point in a 3-2 overtime loss to the Dallas Stars. Despite a strong start, controversial officiating and a key injury to Thomas Chabot impacted the outcome. Read the full analysis.

MEG Energy reports $159M Q3 profit, down from 2024

Canadian oilsands producer MEG Energy reports $159 million in Q3 2025 profit, reflecting year-over-year decline amid changing market conditions. Learn how Alberta's energy sector is adapting.

Toronto's Imperial Pub Closes After 81 Years

Toronto's iconic Imperial Pub closes its doors after 81 years, marking another cultural loss for the city. Read about this legendary establishment's history and legacy.

Pfizer wins $10B obesity drug takeover battle

Pfizer triumphs in dramatic $10 billion bidding war for obesity drug maker Metsera, securing crucial White House-backed deal to compete in weight-loss market. Read the full story.

Senators battle back but fall 3-2 to Bruins in OT

The Ottawa Senators mounted an impressive third-period comeback against the Boston Bruins, forcing overtime before ultimately falling 3-2 in a hard-fought battle at Canadian Tire Centre.

Trump's Plan to Slash Obesity Drug Prices

Former President Donald Trump unveils ambitious strategy to dramatically reduce costs of groundbreaking weight-loss medications, promising relief for millions struggling with obesity.

Canada Goose Q2 Loss Despite Revenue Growth

Canadian luxury outerwear giant Canada Goose reports surprising second-quarter loss despite 1% revenue increase to $281.1 million, as the company navigates wholesale challenges and invests in future growth strategies.

Trump Obesity Drug Deal Boosts Pharma Stocks

Major pharmaceutical giants Novo Nordisk and Eli Lilly experience significant stock surges as former President Donald Trump considers a groundbreaking obesity drug partnership, potentially revolutionizing weight loss treatment accessibility.

Page 3 of 4